The University of Dundee has announced a new partnership with Eisai, one of the world’s leading research-based pharmaceutical companies, aiming to create innovative new drugs for the cancer field. The collaboration combines the world-leading expertise and technology of Professor Alessio Ciulli in PROTACs research at Dundee with Eisai’s discovery research and clinical development experiences in oncology. PROTACs represent a new class of drug candidates with...
Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) focused on viral vector drug substance production, and Symbiosis Pharmaceutical Services (Symbiosis), a contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable viral vector drug products, today announced the successful completion of their collaboration to develop synergistic and world leading capabilities. Intended to accelerate the clinical and commercial production of viral vectors,...
NuCana plc (NASDAQ: NCNA) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company’s investigational drug, Acelarin® (NUC-1031), for the treatment of biliary tract cancer. Acelarin is a new chemical entity and is NuCana’s ProTide transformation of gemcitabine. “We are pleased to have received orphan drug designation from the FDA for Acelarin in biliary tract cancer,” said Hugh...
UK Steel Enterprise has provided more than £100 million of financial support to aspiring businesses across the UK following its latest deal, its board has revealed. The organisation recently agreed a six-figure deal with dynamic Scottish biopharmaceutical firm, Antibody Analytics. While visiting the company at its premises in Lanarkshire’s BioCity, managing director Simon Hamilton confirmed that the investment had brought the total amount of funding...
The fight against superbugs could be helped by the discovery of a potential therapy based on the body’s natural immune defences. Scientists have found that a molecule produced by the body – called LL-37 – changes the way cells behave when they are invaded by bacteria. Fire alarm The molecule acts like a fire alarm, experts say, warning the body’s immune system of the infection...
Ubiquigent Limited, a company focused on enabling and supporting ubiquitin system-focused drug discovery, announced today that it had entered into an agreement with Dorian Therapeutics to provide access to one of its novel small molecule libraries specifically designed to target deubiquitylase (DUB) enzymes. Under the terms of the agreement Ubiquigent will provide Dorian with access to the library as both a physical compound collection and...